Black Spade Acquisition II Company (BSII) Fundamental Analysis & Valuation

NASDAQ:BSII • KYG1153L1095

9.99 USD
+0.49 (+5.16%)
At close: Jun 4, 2025
25 USD
+15.01 (+150.25%)
After Hours: 6/4/2025, 8:08:51 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BSII fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

Taking everything into account, BSII scores 1 out of 10 in our fundamental rating. BSII was compared to 0 industry peers in the Unkown industry. The financial health of BSII is average, but there are quite some concerns on its profitability. BSII does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. BSII Profitability Analysis

1.1 Basic Checks

  • BSII had positive earnings in the past year.
BSII Yearly Net Income VS EBIT VS OCF VS FCFBSII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 0 500K -500K 1M -1M

1.2 Ratios

Industry RankSector Rank
ROA 0.78%
ROE 0.82%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BSII Yearly ROA, ROE, ROICBSII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 0 0.5 -0.5

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BSII so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BSII Yearly Profit, Operating, Gross MarginsBSII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. BSII Health Analysis

2.1 Basic Checks

  • BSII has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BSII Yearly Shares OutstandingBSII Yearly Shares OutstandingYearly Shares Outstanding 2024 5M 10M 15M
BSII Yearly Total Debt VS Total AssetsBSII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2024 50M 100M 150M

2.2 Solvency

  • There is no outstanding debt for BSII. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
BSII Yearly LT Debt VS Equity VS FCFBSII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2024 0 50M 100M 150M

2.3 Liquidity

  • BSII has a Current Ratio of 0.84. This is a bad value and indicates that BSII is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BSII has a Quick Ratio of 0.84. This is a bad value and indicates that BSII is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.84
BSII Yearly Current Assets VS Current LiabilitesBSII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2024 500K 1M 1.5M 2M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. BSII Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. BSII Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 166.50 indicates a quite expensive valuation of BSII.
  • Compared to an average S&P500 Price/Earnings ratio of 25.70, BSII is valued quite expensively.
Industry RankSector Rank
PE 166.5
Fwd PE N/A
BSII Price Earnings VS Forward Price EarningsBSII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BSII Per share dataBSII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BSII Dividend Analysis

5.1 Amount

  • BSII does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BSII Fundamentals: All Metrics, Ratios and Statistics

Black Spade Acquisition II Company

NASDAQ:BSII (6/4/2025, 8:08:51 PM)

After market: 25 +15.01 (+150.25%)

9.99

+0.49 (+5.16%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners20.86%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap191.01M
Revenue(TTM)N/A
Net Income(TTM)1.24M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 166.5
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.26
EV/EBITDA N/A
EPS(TTM)0.06
EY0.6%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS7.96
TBVpS7.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.78%
ROE 0.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.84
Quick Ratio 0.84
Altman-Z N/A
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Black Spade Acquisition II Company / BSII FAQ

What is the ChartMill fundamental rating of Black Spade Acquisition II Company (BSII) stock?

ChartMill assigns a fundamental rating of 1 / 10 to BSII.


Can you provide the valuation status for Black Spade Acquisition II Company?

ChartMill assigns a valuation rating of 0 / 10 to Black Spade Acquisition II Company (BSII). This can be considered as Overvalued.


What is the profitability of BSII stock?

Black Spade Acquisition II Company (BSII) has a profitability rating of 0 / 10.


What is the valuation of Black Spade Acquisition II Company based on its PE and PB ratios?

The Price/Earnings (PE) ratio for Black Spade Acquisition II Company (BSII) is 166.5 and the Price/Book (PB) ratio is 1.26.


What is the financial health of Black Spade Acquisition II Company (BSII) stock?

The financial health rating of Black Spade Acquisition II Company (BSII) is 4 / 10.